Related Experiment Video

Updated: Aug 2, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Beta-adrenergic blocking agents: their current status

B K Clark

    AACN Clinical Issues in Critical Care Nursing
    |May 1, 1992
    PubMed

    More Related Videos

    Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding10:13

    Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

    Published on: June 9, 2017

    Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro09:41

    Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

    Published on: March 17, 2023

    Related Concept Videos

    Adrenergic Receptors: β Subtype01:26

    Adrenergic Receptors: β Subtype

    β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
    Isoprenaline > Adrenaline > Noradrenaline
    Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
    β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
    Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

    Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

    Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
    Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

    α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
    α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...